Targanta (Cambridge, MA) developer of antibacterial pro-drugs raised closed a $70M Series C financing led by Brookside Capital, Skyline Ventures, Radius and OrbiMed Advisors. Existing investors Seaflower Ventures, VenGrowth and the Canadian Medical Discoveries Fund also participated.